Clinical data
Trade names Entereg
Synonyms Alvimopan, Entereg
AHFS/ Monograph
MedlinePlus a608051
License data
  • US: B (No risk in non-human studies)
    Routes of
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Bioavailability 6%
    Protein binding 80% (parent drug), 94% (metabolite)
    Metabolism Gut microflora-mediated hydrolysis to active metabolite
    Elimination half-life 10-17 hours
    Excretion Faeces, urine (35%)
    CAS Number
    PubChem CID
    Chemical and physical data
    Formula C25H32N2O4
    Molar mass 424.53 g/mol
    3D model (JSmol)
     NY (what is this?)  (verify)

    Alvimopan (trade name Entereg) is a drug which behaves as a peripherally acting μ-opioid antagonist. With the limited ability to cross the blood–brain barrier and reach the μ-opioid receptors of the central nervous system, the clinically undesirable effects of centrally acting opioid antagonists (like reversal of opioid-mediated analgesia) are avoided without affecting the intended blockade of μ-opioid receptors in the gastrointestinal tract.[1][2] It is currently only Food and Drug Administration approved for the treatment of postoperative ileus which it received in May 2008.[3][4]

    Medical uses

    Alvimopan is indicated in people to avoid postoperative ileus following partial large or small bowel resection with primary anastomosis. Alvimopan accelerates the gastrointestinal recovery period as defined by time to first bowel movement or flatus.[5]

    Adverse effects

    The most common side effects associated with alvimopan are:[1]

    Adverse Effect Frequency (%) with placebo Frequency (%) with alvimopan
    Dyspepsia 4.6 7.0
    Hypokalemia 8.5 9.5
    Back Pain 1.7 3.3
    Delayed Micturition 2.1 3.2


    Alvimopan is absolutely contraindicated in patients who have taken therapeutic doses of opioids for more than seven consecutive days immediately prior to when alvimopan would be initiated because individuals with recent exposure to opioids are expected to be more sensitive to the effects of μ-opioid receptor antagonists. The peripheral site of action of alvimopan suggests that such a heightened sensitivity would precipitate gastrointestinal effects beyond dyspepsia.[5]


    Alvimopan is not a substrate for the cytochrome P450 enzyme system. Therefore, no interactions are expected with hepatically metabolized drugs. Alvimopan is substrate for P-glycoprotein. Thus, interactions are to be expected with known P-glycoprotein inhibitors such as amiodarone, bepridil, diltiazem, ciclosporin, itraconazole, quinine, quinidine, spironolactone, and verapamil.[5]


    Mechanism of action

    Alvimopan competitively binds to μ-opioid receptor in the gastrointestinal tract. Unlike methylnaltrexone (another peripherally acting μ-receptor antagonist) that bears a quaternary amine, alvimopan owes its selectivity for peripheral receptors to its kinetics. Alvimopan binds to peripheral μ-receptors with a Ki of 0.2 ng/mL and dissociates more slowly than most other ligands.[5]



    Peak plasma concentration (Cmax) of alvimopan is reached approximately 2 hours after oral dosing, while the Cmax for metabolite occurs 36 hours after an oral dose. Alvimopan's high affinity for the peripheral μ-receptor results in an absolute bioavailability less than 7%. [5]


    80% to 90% of systemically available alvimopan is bound to plasma protein. At steady state, the volume of distribution is approximately 30 liters.[5]


    Alvimopan undergoes no significant hepatic metabolism, but is metabolized by intestinal flora. Gut metabolism produces an active metabolite with no clinically significant contribution to drug effect.[5]


    Alvimopan undergoes 35% renal excretion and greater than 50% biliary excretion. Drug metabolized by intestinal flora is excreted in the feces. Alvimopan's half-life of elimination is 10 to 17 hours, while that of the gut metabolite is 10 to 18 hours.[5]

    Dosing and administration

    Alvimopan is only approved for short term use of no more than 15 doses. It is available on an inpatient basis at institutions approved by and registered with the Entereg Access Support and Education (E.A.S.E.) program. A person should receive no more than 15 doses.[5]

    See also


    1. 1 2 Neary P, Delaney P (2005). "Alvimopan". Expert Opin Investig Drugs. 14 (4): 479–88. doi:10.1517/13543784.14.4.479. PMID 15882122.
    2. Schmidt WK (2001). "Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist". Am J Surg. 182 (5A Supp): 27S–38S. doi:10.1016/S0002-9610(01)00784-X. PMID 11755894.
    3. FDA press release - FDA Approves Entereg to Help Restore Bowel Function Following Surgery
    4. Sharma, A; Jamal, MM (July 2013). "Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies". Current Gastroenterology Reports. 15 (7): 334. doi:10.1007/s11894-013-0334-4. PMID 23836088.
    5. 1 2 3 4 5 6 7 8 9 Alvimopan Product Label as approved by the FDA on May 20, 2008.

    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.